Soleno Therapeutics (SLNO) Q3 2025: Revenue Doubles as VICAT-XR Adoption Hits 764 Patients

November 4, 2025 | By EarningsIQ Research

Soleno Therapeutics delivered a pivotal Q3, with VICAT-XR, its Prader-Willi syndrome therapy, driving a revenue surge and first-time profitability. Despite a temporary slowdown linked to a short-seller report and seasonal effects, the company maintained strong prescriber expansion and broad payer access. As Soleno advances its EU regulatory push, the U.S. launch trajectory and patient engagement will determine the next phase of growth.

Summary

• VICAT-XR Launch Momentum: Rapid patient uptake and prescriber growth continue despite mid-quarter disruption.
• Commercial Execution: Broad payer coverage and robust patient education underpin market penetration.
• Global Expansion Path: EU regulatory progress positions Soleno for addressable market growth in 2026.

Performance Analysis

Soleno’s third quarter marked a transformative inflection, as net revenues more than doubled sequentially, propelled by accelerating adoption of VICAT-XR, the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS). The company reported 764 active patients at quarter end, a significant ramp from launch, and expanded its prescriber base to 494 unique physicians. This expansion reflects both pent-up demand and effective field execution, with over 50 percent of top 300 providers now engaged.

Profitability was achieved for the first time, supported by a strong cash position following a July equity raise. Operational leverage was evident as cost of goods sold remained low, though management noted this will normalize as zero-cost inventory is depleted. Despite a mid-quarter dip in patient starts and increased discontinuations following a short-seller report, the underlying demand drivers and payer access remained intact.

• Patient Funnel Dynamics: Start forms totaled 1,043 since launch, with 397 in Q3, and a typical 30-day lag from start form to therapy initiation.
• Prescriber Penetration: 199 new prescribers added in Q3, with strong momentum beyond academic centers into community practices.
• Payer Access Milestone: Coverage now extends to 132 million lives, including all major PBMs and 40 state Medicaid programs.

While a summer slowdown and external noise briefly altered the launch curve, management’s commentary and field data suggest the growth foundation remains robust, with room for further penetration among existing and new prescribers.

Executive Commentary

Strategic Positioning

1. VICAT-XR as Standard of Care in PWS

Soleno is leveraging its first-mover advantage with VICAT-XR, targeting the estimated 10,000-12,000 PWS patient population in the U.S. The company’s education-driven approach, including the PACE team, patient webinars, and expert-on-demand physician programs, aims to entrench VICAT-XR as the default therapy for hyperphagia, a hallmark and life-threatening symptom in PWS. Early real-world data confirm alignment with clinical trial safety and efficacy, with most discontinuations occurring early and predominantly for non-serious adverse events.

2. Payer Access and Reimbursement Strategy

Rapid payer policy wins have neutralized a key prescriber adoption barrier. With coverage across commercial, Medicare, and Medicaid channels, and inclusion by all top three PBMs (Pharmacy Benefit Managers, companies managing prescription drug benefits), Soleno’s field teams focus on expediting reimbursement and supporting clinics in navigating prior authorizations. The company targets a 30-day fill rate from start form to therapy, smoothing the path for both patients and physicians.

3. Prescriber Base Expansion and TAM Penetration

Soleno’s reach now spans both academic KOLs (Key Opinion Leaders) and community treaters, with over half of top providers engaged and a growing share of scripts from new, less experienced prescribers. The company’s claims database and machine learning initiatives further enable precise patient targeting and efficient sales force deployment. Management sees significant room to grow within the existing prescriber base as clinics ramp up and revisit eligible patients during routine visits.

4. International Growth Levers

Regulatory progress in the EU is a clear near-term catalyst. Soleno’s DCCR (Diazoxide Choline Controlled-Release, the compound marketed as VICAT-XR in the U.S.) marketing application is under EMA review, with day 120 questions received and responses in process. The combined addressable population in the five largest EU countries is estimated at 9,500, with high diagnostic rates and centralized care, suggesting a receptive market if approved.

Key Considerations

Q3’s results reinforce the durability of Soleno’s commercial model, but also surface execution watchpoints as the launch matures.

Key Considerations:

• Short-Report Impact: A mid-August short-seller report temporarily elevated discontinuation rates and slowed new patient starts, highlighting the sensitivity of rare disease launches to external narratives.
• Adverse Event Management: Most discontinuations stemmed from non-serious, on-label adverse events like edema and mild hyperglycemia, underscoring the need for ongoing prescriber and patient education.
• Prescriber Learning Curve: Community physicians with limited PWS experience require additional support to manage side effects and optimize dosing, a focus of Soleno’s field and education programs.
• Inventory Accounting Transition: Cost of goods sold will rise as zero-cost inventory is replaced with at-cost batches, impacting future gross margin trajectories.
• EU Approval Timeline: The regulatory process in Europe mirrors the U.S. pathway, but the pace and outcome remain uncertain, with meaningful upside if successful.

Risks

Soleno faces several launch-phase risks, including continued vulnerability to misinformation or adverse publicity, prescriber hesitancy among non-specialists, and the challenge of sustaining patient adherence amid early side effects. The normalization of cost structure as inventory cycles could pressure margins, while EU approval is not guaranteed and competitive threats (such as Rhythm’s melanotide program) are on the horizon. Management does not plan intra-quarter disclosures, limiting near-term visibility for investors.

Forward Outlook

For Q4 2025, Soleno did not provide formal guidance but signaled:

• Continued patient and prescriber growth, with a steady, rather than bolus, trajectory expected as clinics ramp up.
• Stable payer access and ongoing investment in education and access resources.

For full-year 2025, management withheld annualized revenue guidance, citing the need for further launch maturation. Key factors highlighted include:

• Seasonality and holiday effects unique to the PWS population
• Ongoing education efforts targeting both new and existing prescribers

Takeaways

• Launch Trajectory Intact: Despite a summer pause, VICAT-XR’s adoption and access fundamentals remain robust, with significant headroom among both existing and new prescribers.
• Execution Focus: Patient engagement, adverse event management, and prescriber education will determine the pace of future growth as the market transitions from early adopters to broader community uptake.
• Global Optionality: EU regulatory progress and future competitive dynamics will shape Soleno’s long-term value proposition and market share potential.

Conclusion

Soleno Therapeutics’ Q3 results confirm a resilient commercial launch, with VICAT-XR rapidly establishing itself as the standard of care for PWS-related hyperphagia. Sustained execution in prescriber support, payer access, and international expansion will be crucial to maintaining growth and defending market leadership as the rare disease landscape evolves.

Industry Read-Through

The rare disease launch playbook is evolving, with Soleno’s experience underscoring the importance of proactive education, rapid payer engagement, and real-world data transparency. Competitors in rare and ultra-orphan indications should note the volatility introduced by external narratives and the operational risk posed by non-specialist prescribers. As the field matures, companies that blend targeted field execution with digital patient finding and robust stakeholder engagement will be best positioned to drive durable adoption and defend premium pricing. The European regulatory pathway remains a critical growth lever for U.S.-centric rare disease franchises.

SLNO Healthcare Biotechnology Rare Disease Drug Launch Payer Access Commercialization EU Expansion